A 28-year-old nulliparous woman with PCOS and BMI 32 kg/m² presents with primary infertility for 2 years. She has irregular menses (cycle length 45–90 days), hirsutism, and elevated androgen levels. Baseline investigations show FSH 6 IU/L, LH 18 IU/L, and normal prolactin. She was counselled on lifestyle modification for 3 months without improvement. You decide to initiate ovulation induction. Which of the following is the MOST appropriate first-line pharmacological agent and the rationale for its choice in this clinical scenario?

Explanation

## Correct Answer: Letrozole 2.5 mg daily from day 3–7 of cycle ### Rationale Letrozole is now the preferred first-line agent for ovulation induction in PCOS, particularly in patients with elevated baseline LH and/or elevated androgens. The evidence supporting letrozole over clomiphene in PCOS includes: **Key Point:** Letrozole is an aromatase inhibitor that: - Blocks peripheral conversion of androgens to estrogen - Reduces estrogen-mediated negative feedback on the hypothalamus and pituitary - Allows preferential FSH-driven follicular development - Results in **lower serum androgen levels** during the follicular phase compared to clomiphene - Produces **higher pregnancy rates** and **lower miscarriage rates** in PCOS (PCOS Collaborative Metformin Trial, Cochrane reviews) - Does NOT cause anti-estrogenic effects on endometrium (unlike clomiphene) - Avoids the risk of ovarian hyperstimulation syndrome (OHSS) seen with gonadotropins **Clinical Pearl:** In PCOS with elevated LH, letrozole's mechanism of reducing androgen production is superior to clomiphene's mechanism of increasing FSH, because: 1. High baseline LH already drives excessive androgen production in theca cells 2. Clomiphene further increases LH (via reduced negative feedback), worsening hyperandrogenism 3. Letrozole suppresses androgen production while allowing FSH to act on follicles with lower androgen interference **High-Yield:** Letrozole is now preferred over clomiphene in PCOS (ASRM 2013, NICE 2013, ACOG 2020 guidelines). --- ## Why Each Distractor Is Wrong ### Option 0: Clomiphene citrate **Problem:** While clomiphene is effective in non-PCOS anovulation, it is **NOT first-line in PCOS with elevated LH and androgens** because: - Clomiphene increases LH secretion (by blocking estrogen feedback at pituitary), which **worsens hyperandrogenism** in PCOS - Results in **higher miscarriage rates** and **lower live birth rates** compared to letrozole in PCOS (Legro et al. NEJM 2014) - Causes anti-estrogenic effects on endometrium, reducing endometrial thickness - Clomiphene remains first-line only in non-PCOS anovulation (e.g., hypothalamic amenorrhea) ### Option 2: Gonadotropins with GnRH agonist **Problem:** While gonadotropins are effective, they are **NOT first-line** because: - Reserved for clomiphene-resistant or letrozole-resistant PCOS (second/third-line) - Require intensive monitoring (serial ultrasound, estradiol levels) and are more costly - Carry higher risk of OHSS in PCOS (which has multiple follicles at baseline) - GnRH agonist co-treatment is used to prevent premature LH surge, but this is unnecessary with letrozole (which suppresses androgens and allows FSH dominance) - Indicated when simple ovulation induction fails, not as initial therapy ### Option 3: Metformin monotherapy for 3 months **Problem:** While metformin improves insulin sensitivity and may restore ovulation in lean PCOS, it is **NOT appropriate as monotherapy** in this patient because: - This patient has already failed **3 months of lifestyle modification** (which is the standard first step) - Metformin alone has lower ovulation rates (~30%) compared to letrozole (~70–80%) in PCOS - Metformin is best used as an **adjunct** to letrozole (or clomiphene) in insulin-resistant PCOS, not as monotherapy after failed lifestyle intervention - Delaying pharmacological ovulation induction by another 3 months of metformin monotherapy is not evidence-based in a patient with 2 years of infertility - Metformin is indicated for metabolic management and may improve outcomes when combined with ovulation induction agents --- ## Summary Table | Agent | First-line in PCOS? | Mechanism | Pregnancy Rate in PCOS | Key Limitation | |-------|-------------------|-----------|------------------------|----------------| | **Letrozole** | **YES** | Aromatase inhibitor; ↓ androgens, ↑ FSH effect | 70–80% | Off-label use (not FDA-approved for PCOS, though widely used) | | Clomiphene | No (non-PCOS only) | SERM; ↑ FSH, but also ↑ LH | 50–60% in PCOS | Worsens hyperandrogenism; ↓ endometrial thickness | | Gonadotropins | Second-line | Exogenous FSH ± hCG | 80–90% | High cost, OHSS risk, intensive monitoring | | Metformin | Adjunct only | ↑ Insulin sensitivity | 30–40% monotherapy | Slow onset; use with letrozole/clomiphene | --- ## Key References - **Legro et al. (NEJM 2014):** Letrozole vs. clomiphene in PCOS — letrozole superior for live birth rate - **ASRM Guidelines (2013):** Letrozole preferred over clomiphene in PCOS - **NICE Guidelines (2013):** Letrozole first-line for PCOS ovulation induction - **Cochrane Review (2014):** Letrozole more effective than clomiphene in PCOS